Suzuki Takatoshi, Tsujino Ichizo, Harabayashi Wataru, Shima Hideki, Nakamura Junichi, Sato Takahiro, Suzuki Masaru, Takeda Yukari, Konno Satohi
Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, N15, W7, Kita-ku, Sapporo, 060-8638, Japan.
Department of Hematology, Tonan Hospital, N4, W7, Kita-ku, Sapporo, 060-0004, Japan.
Respir Med Case Rep. 2023 May 11;44:101867. doi: 10.1016/j.rmcr.2023.101867. eCollection 2023.
An 80-year-old man diagnosed with primary macroglobulinemia 7 years earlier had been treated with cyclophosphamide, following which he developed dyspnea on exertion. Cyclophosphamide was discontinued. The patient's dyspnea, however, failed to improve. Right heart catheterization (RHC) revealed precapillary pulmonary hypertension (PH). He was transferred to our institution for further examination. Prior use of cyclophosphamide was the patient's only risk factor for PH, and cyclophosphamide use was considered as a possible cause of PH in this case. He was treated with tadalafil and dyspnea gradually improved. A follow-up RHC exhibited improvement in mean pulmonary arterial pressure and pulmonary vascular resistance.
一名80岁男性,7年前被诊断为原发性巨球蛋白血症,曾接受环磷酰胺治疗,之后出现劳力性呼吸困难。停用环磷酰胺后,患者的呼吸困难仍未改善。右心导管检查(RHC)显示毛细血管前性肺动脉高压(PH)。他被转至我院作进一步检查。既往使用环磷酰胺是该患者发生PH的唯一危险因素,在本病例中,使用环磷酰胺被认为是PH的可能病因。他接受了他达拉非治疗,呼吸困难逐渐改善。随访的右心导管检查显示平均肺动脉压和肺血管阻力有所改善。